LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.61
-0.02 (-3.39%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.63
Open0.62
Bid0.60 x 1400
Ask0.65 x 1400
Day's Range0.60 - 0.66
52 Week Range0.60 - 6.50
Volume575,548
Avg. Volume1,035,714
Market Cap18.196M
Beta3.01
PE Ratio (TTM)N/A
EPS (TTM)-1.66
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.67
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of LIFE earnings conference call or presentation 14-Aug-18 9:00pm GMT

    Q2 2018 aTyr Pharma Inc Earnings Call

  • Associated Press2 days ago

    Atyr Pharma: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 66 cents. A year ago, they were trading at $3.25. ...

  • GlobeNewswire2 days ago

    aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update

    SAN DIEGO, Aug. 14, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating ...

  • ACCESSWIRE2 days ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 5:00 PM Eastern Time. ...

  • GlobeNewswire8 days ago

    aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018

    SAN DIEGO, Aug. 08, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will ...

  • GlobeNewswire17 days ago

    aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer

    SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Jill Broadfoot has joined aTyr as Chief Financial Officer. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals plc, from May 2016 to January 2017.

  • GlobeNewswire22 days ago

    aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference

    SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster presentation at the Scleroderma Foundation National Patient Education Conference to be held in Philadelphia, PA from July 27 – 29, 2018. The presentation reviews the positive lung and skin results of a recently completed murine experiment evaluating low doses of ATYR1923 in a chronic graft versus host disease model of systemic sclerosis. “The data we are presenting tomorrow are part of our ongoing estate of translational animal models set to help inform and de-risk our upcoming clinical development of ATYR1923,” stated David King, Ph.D., aTyr’s Chief Scientific Officer.

  • GlobeNewswire2 months ago

    aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate

    SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced positive data from its Phase 1 clinical trial of ATYR1923, an immuno-modulatory therapeutic candidate with potentially broad therapeutic application in the treatment of interstitial lung diseases. This first-in-human, randomized, double-blind, placebo-controlled study was designed to investigate the safety, tolerability, immunogenicity and pharmacokinetics of intravenous ATYR1923 in healthy volunteers.  The Phase 1 study enrolled 36 healthy volunteers who were randomized to one of six cohorts and received a single infusion of intravenous ATYR1923 or placebo.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT

    Q4 2017 aTyr Pharma Inc Earnings Call

  • GlobeNewswire3 months ago

    aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference

    SAN DIEGO, May 31, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT

    Q1 2018 aTyr Pharma Inc Earnings Call

  • Associated Press3 months ago

    Atyr Pharma: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 36 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • ACCESSWIRE3 months ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 8:00 AM Eastern Time. To listen ...

  • aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
    Zacks5 months ago

    aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?

    aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?

  • Associated Press5 months ago

    Atyr Pharma reports 4Q loss

    The San Diego-based company said it had a loss of 39 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • ACCESSWIRE5 months ago

    aTyr Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018, at 5:00 PM Eastern Time. ...